Search results for "Monacolin"

showing 3 items of 3 documents

Bioactive triterpenes of protium heptaphyllum gum resin extract display cholesterol-lowering potential

2021

Hypercholesterolemia is one of the major causes of cardiovascular disease, the risk of which is further increased if other forms of dyslipidemia occur. Current therapeutic strategies include changes in lifestyle coupled with drug administration. Statins represent the most common therapeutic approach, but they may be insufficient due to the onset of resistance mechanisms and side effects. Consequently, patients with mild hypercholesterolemia prefer the use of food supplements since these are perceived to be safer. Here, we investigate the phytochemical profile and cholesterol-lowering potential of Protium heptaphyllum gum resin extract (PHE). Chemical characterization via HPLC-APCI-HRMS2 and…

0301 basic medicineModels MolecularProtein ConformationDrug Evaluation Preclinical030204 cardiovascular system & hematologyPharmacologyPPARαTerpenelcsh:ChemistryPCSK9chemistry.chemical_compound0302 clinical medicineCatalytic DomainSettore BIO/10 - BiochimicaPlant Gumslcsh:QH301-705.5SpectroscopyChromatography High Pressure LiquidFlame IonizationMonacolinChemistryAnticholesteremic AgentsGeneral MedicineComputer Science ApplicationsMolecular Docking SimulationCholesterolPhytochemicalMolecular dockinglipids (amino acids peptides and proteins)Breu brancoStatinmedicine.drug_classHypercholesterolemiaArticleCatalysisGas Chromatography-Mass SpectrometryInorganic Chemistry03 medical and health sciencesNutraceuticalmedicineHumansLovastatinPhysical and Theoretical ChemistryMolecular BiologyOleananeHMGCREnzymatic activityCholesterolPCSK9Organic ChemistryStatinSettore CHIM/08 - Chimica FarmaceuticaTriterpenes030104 developmental biologyhypercholesterolemia; gene expression; HMGCR; PCSK9; PPARα; enzymatic activity; molecular docking; statin; monacolin; breu brancolcsh:Biology (General)lcsh:QD1-999Breu branco; Enzymatic activity; Gene expression; HMGCR; Hypercholesterolemia; Molecular docking; Monacolin; PCSK9; PPARα; StatinLDL receptorDietary SupplementsHepatocytesSettore BIO/14 - FarmacologiaGene expressionHydroxymethylglutaryl-CoA Reductase InhibitorsResins PlantHydrogen
researchProduct

Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study

2015

Abstract The main guidelines for cardiovascular disease prevention suggest that nutraceuticals could be an efficacious tool to improve lipid pattern. Our aim was to carry out a clinical trial comparing the metabolic effects of a combined nutraceutical containing both red yeast rice and polyunsaturated fatty acids (PUFAs) and a phytosterol-based approach in a setting of clinical practice. This was a multicenter open study with parallel control. We consecutively enrolled 107 pharmacologically untreated subjects affected by primary polygenic hypercholesterolemia and metabolic syndrome, assigned to 8-week treatment with a combined treatment with red yeast rice (Dif1Stat®, including 5 mg monacol…

MaleSettore MED/09 - Medicina InternaMedicine (miscellaneous)PharmacologyTriglycerideDietary supplements; Hypercholesterolemia; Monacolins; Nutraceuticals; Phytosterols; PUFA; Red yeast rice; Medicine (miscellaneous); Nutrition and DieteticsDietary supplementchemistry.chemical_compoundPhytosterolAnticholesteremic AgentMetabolic Syndromechemistry.chemical_classificationMonacolinNutrition and DieteticsAnticholesteremic AgentsPhytosterolPhytosterolsDietary supplements; Hypercholesterolemia; Monacolins; Nutraceuticals; Phytosterols; PUFA; Red yeast rice; Adult; Anticholesteremic Agents; Biological Products; Cholesterol; Cholesterol LDL; Fatty Acids Unsaturated; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Metabolic Syndrome; Middle Aged; Phytosterols; Treatment Outcome; Triglycerides; Dietary Supplements; Medicine (miscellaneous); Nutrition and DieteticsLipidMiddle AgedDietary supplementsLipidsCholesterolTreatment OutcomeBiochemistryFatty Acids UnsaturatedBiological ProductFemalelipids (amino acids peptides and proteins)NutraceuticalNutraceuticalsLovastatinFull CommunicationsHumanmedicine.drugPolyunsaturated fatty acidAdultHypercholesterolemiaBiologyNutraceuticalMonacolinsmedicineRed yeast riceHumansLovastatinTriglyceridesBiological ProductsCholesterolCholesterol LDLmedicine.diseaseClinical trialRed yeast ricechemistryMetabolic syndromePUFAJournal of Medicinal Food
researchProduct

Drug Induced Liver Injury (DILI) due to variability in monacolin K content in Red Yeast Rice (RYR): An expert opinion

2020

Abstract Introduction Red yeast rice (RYR) is an effective cholesterol-lowering nutraceutical reversibly inhibiting 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase. As liver damage is a possible (albeit rare) side effect of HMG-CoA inhibitors, it make sense to focus on the tolerability of the liver to RYR extracts. The aim of this paper is to offer an expert opinion on the risk of liver damage by the use of RYR extract. Methods A review of the available literature has been carried out and critically reviewed by the authors. Results According to a large meta-analysis of 53 randomized clinical trials comprising 112 treatment arms, which included 8535 subjects with 4437 in the RYR arm and …

nutrivigilancesafetyDrugSide effectmedia_common.quotation_subjectliver injury; monacolin K; nutrivigilance; red yeast rice; safety; tolerabilityPharmacologymonacolin K03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalRed yeast rice Liver injury Monacolin K Safety Tolerability NutrivigilanceRed yeast riceMedicinered yeast rice030212 general & internal medicinetolerabilityLiver injury Monacolin K Nutrivigilance Red yeast rice Safety Tolerabilitymedia_commonLiver injurybusiness.industryRyanodine receptormusculoskeletal systemmedicine.disease030205 complementary & alternative medicineCitrininComplementary and alternative medicinechemistryTolerabilitycardiovascular systembusinesstissuesliver injury
researchProduct